The ICI-Lab joint laboratory, a partnership between LIP6 and the company BodyCAP, aims to study and develop smart biomedical electronic devices to aid in the diagnosis of diseases of the intestinal tract. The ICI-Lab benefits from scientific expertise in AI and in embedded systems for biomedical devices of LIP6 and from the know-how and patents in the design and production of "Capsule" type medical devices of BodyCAP. The work carried out within the ICI-Lab involves the integration of digital processing, from low to high level, within video-endoscopic capsules to produce a new generation of medical devices which will allow: i. a multimodal analysis (image, pH, temperature, gas) within an endoscopic capsule; ii. an interpretation of the data for the explicability of the algorithms; iii. the improvement and automation of procedures for analyzing and interpreting images of the intestinal tract; iv. support to the medical teams in establishing a diagnosis; v. the improvement of the follow-up and care of gastroenterology patients. Images acquired by a capsule can sometimes show obstruction of the lumen of the intestine due to the presence of fluid and / or feces. The multi-modality will make it possible upstream to have additional information to the image and to reinforce the discriminatory nature in the detection of polyps. The treatments will be dedicated to the acquisition of the characteristics of the various data (images, pH, temperature, gas) and on their interpretation for the recognition of pathology markers. These will be based on artificial intelligence algorithms, including deep learning, vector support machines and decision trees. The study, design and validation of intelligent endoscopic video capsules are the purpose of this joint laboratory. The pooling of industrial resources and the assets of the 2 stakeholders will make it possible to develop a platform for in-vitro testing and validation using a bio-mechanical intestinal simulator. These tools will make it possible to create a unique test environment to validate the designed devices on a real life scale, in an artificial environment. Thanks to the partnerships already set up by BodyCAP with various technical platforms, validations will be continued on an animal model and in humans, with the aim of bringing innovative devices to the market in 2025 in order to support diagnosis and improve the effectiveness of screening for bowel pathologies.